Publication of Cancellation of Entries for Kinds of Medical Devices from the Australian Register of Therapeutic Goods - Osstem Australia Pty Ltd - 202502

Overview

The Therapeutic Goods Act 1989 (the Act) was enacted to regulate therapeutic goods, including medical devices, to ensure their quality, safety, and efficacy. The Act was introduced to address the need for a comprehensive regulatory framework that governs the import, export, supply, and advertisement of therapeutic goods in Australia. This legislation is administered by the Parliament of Australia and its primary policy objective is to protect public health by ensuring that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. The Act provides mechanisms for the regulation of therapeutic goods through a system of registration and approval, and includes provisions for the monitoring and enforcement of compliance. The cancellation of the ARTG entry of a particular medical device, as evidenced in the 2013 gazette, reflects the Act's role in maintaining stringent regulatory standards and ensuring that only those therapeutic goods that meet the required conformity assessment procedures are available in the Australian market.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of entities, including individuals and companies involved in the manufacture, supply, importation, and advertising of therapeutic goods in Australia. This includes medical devices, which are subject to specific regulatory controls to ensure their safety, quality, and efficacy. The Act applies to the Commonwealth and all states and territories of Australia, providing a uniform regulatory framework for the oversight of therapeutic goods across the nation. However, the Act does not apply to goods that are covered by other legislation, such as food, cosmetics, or other regulated products. Additionally, certain therapeutic goods may be exempt from certain provisions of the Act, such as those used for personal use or research purposes. The application and scope of the Act can be further extended or restricted through subordinate instruments, such as regulations or guidelines issued by the Therapeutic Goods Administration. In this specific case, the Therapeutic Goods Act 1989 was applied to cancel the ARTG entry of a dental implant manufactured by Osstem Implant Co Ltd. The cancellation was initiated by the delegate of the Secretary to the Department of Health and Ageing, Rodolfo Ferrari, due to the sponsor's failure to provide evidence that the manufacturer had applied the appropriate conformity assessment procedure to the device. Consequently, the certifications made under section 41FD(f) and (g) of the Act at the time of the application were deemed incorrect. This decision highlights the importance of compliance with the regulatory requirements set out in the Act and the potential consequences for non-compliance, which may include the cancellation of ARTG entries and restrictions on the supply or use of therapeutic goods in Australia.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) includes a number of sections that govern the regulation of therapeutic goods, including medical devices, in Australia. In particular, section 41GP(1) provides that the Secretary may cancel an entry in the Australian Register of Therapeutic Goods (ARTG) if certain conditions are met, while section 41GN(1)(f) allows for the cancellation of an entry if the sponsor fails to provide evidence that the manufacturer has applied the appropriate conformity assessment procedure to the device. This is the basis for the cancellation of the ARTG entry of a kind of medical device for the dental implant gauge, depth, with ARTG number 202502, as announced in the Gazette. Under the Act, the sponsor of a medical device is responsible for ensuring that the manufacturer applies the appropriate conformity assessment procedure to the device, and for providing evidence of this to the Department of Health and Ageing. Failure to do so may result in the cancellation of the ARTG entry, as occurred in this case. Additionally, the manufacturer of the device is responsible for ensuring that the appropriate conformity assessment procedure is applied, and for providing any necessary evidence to the sponsor. The Act also imposes obligations on both the sponsor and the manufacturer to comply with applicable regulations and standards, and to maintain accurate and up-to-date records. Breach of the obligations and requirements set out in the Act may result in a range of civil and criminal penalties. Under section 41HA of the Act, an individual or entity that contravenes certain provisions of the Act may be subject to a civil penalty of up to $222,200 for a corporation, or $44,440 for any other individual or entity. Additionally, under section 41HB, an individual who is responsible for a contravention of the Act may be subject to a criminal penalty of up to five years imprisonment, or a fine of up to $333,300 for a corporation, or $66,600 for any other individual. The maximum penalties for breaches of the Act are therefore significant, and highlight the importance of compliance with the obligations and requirements set out in the Act. In this case, the cancellation of the ARTG entry serves as a warning to sponsors and manufacturers of the consequences of failing to meet their obligations under the Act.